Trials / Conditions / Metastases, Neoplasm

Metastases, Neoplasm

26 registered clinical trials studyying Metastases, Neoplasm — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas NCT05419518	Rutgers, The State University of New Jersey	Phase 2
Unknown	Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CAR NCT03563326	Jian-Kun Hu	Phase 1
Completed	Surgical Treatment of Pancreatic RCC Metastases NCT03670992	Azienda Policlinico Umberto I	—
Completed	Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Met NCT02265549	Maastricht Radiation Oncology	—
Terminated	A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors NCT01115803	Eli Lilly and Company	Phase 1
Completed	A Study in Patients With Advanced or Metastatic Cancer NCT01115751	Eli Lilly and Company	Phase 1
Terminated	Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in NCT00065117	AstraZeneca	Phase 2
Completed	A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of NCT00055471	AstraZeneca	Phase 2
Terminated	Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer NCT00050336	Merck Sharp & Dohme LLC	Phase 3
Terminated	Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer NCT00048893	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma NCT00044863	Eli Lilly and Company	Phase 2
Completed	This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer NCT00034918	Genzyme, a Sanofi Company	Phase 2
Completed	Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma NCT00056173	Aptose Biosciences Inc.	Phase 1 / Phase 2
Completed	High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors NCT00037869	M.D. Anderson Cancer Center	Phase 3
Completed	Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekl NCT00039780	BioNumerik Pharmaceuticals, Inc.	Phase 3
Completed	Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver NCT00041808	FeRx	Phase 1 / Phase 2
Terminated	Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) NCT00034697	Merck Sharp & Dohme LLC	Phase 2
Completed	Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer NCT00046527	Celgene Corporation	Phase 3
Completed	ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer NCT00046514	Celgene Corporation	Phase 2
Completed	Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients NCT00037609	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies NCT00046423	Celgene Corporation	Phase 1
Withdrawn	Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole NCT00038038	M.D. Anderson Cancer Center	N/A
Completed	A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Me NCT00035035	Eli Lilly and Company	Phase 3
Completed	Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) NCT00054795	Pharmacyclics LLC.	Phase 3
Completed	A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma NCT00035061	Eli Lilly and Company	Phase 2
Unknown	Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lun NCT00040560	Copharos	Phase 1